Evaluation Of Hepcidin And Iron Concentrations With Liver And Kidney Functions In Beta-Thalassemia Patients

Othman R Al Samarraı; Hazem Mohammed Abd; Mohammed Hameed Mahal; Ali Rasheed Hameed Al Samarrai

doi:10.17776/csj.1562338

EN

Evaluation Of Hepcidin And Iron Concentrations With Liver And Kidney Functions In Beta-Thalassemia Patients

Abstract

The goal of this research was to estimate the concentrations of iron and hepcidin with liver and kidney functions in beta-thalassemia patients, the study involved the collection of 80 blood samples from both sexes, and the samples were distributed into 45 samples for beta thalassemia patients, their ages ranged between 15-25 years, the samples were collected from the Thalassemia Specialization Center in Baquba General Hospital, and 35 blood samples for healthy people as a control group, their ages extended from 15 to 25. years, during the period from the beginning of March 2023 until the end of May 2023. The study's findings revealed a considerable increase in the concentrations of hepcidin and iron in patients group compared with the healthy ones. It also displayed a significant reduce in the patients' albumin and creatinine concentrations as compared with healthy group, while the results here were no significant variations in total protein, urea and uric acid levels.

Keywords

References

[1] Oltean A., & IM C.. Mentzer Index in pediatric thalassemia trait, Jurnalul Pediatrului, 23 (89-90) (2020) 35-40.
[2] JLT J. M. B. Lubert Stryer editor, BIOCHEMISTRY. 5th ed. W. H. Freeman, (2002) 596. ISBN-10: 0716746840, ISBN-13: 978-0716746843.
[3] Rivella S., β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies, Haematologica, 100 (4) (2015) 418.
[4] Bajwa H., Basit H., Thalassemia, StatPearls Publishing, Treasure Island (FL), 2023.
[5] Mathur S., Sutton J., Personalized medicine could transform healthcare, Biomedical Reports, 7 (1) (2017) 3-5.
[6] Danjou F., Anni F., Galanello R., Beta-thalassemia: from genotype to phenotype, Haematologica, 96 (11) (2011) 1573.
[7] Prathyusha K., Venkataswamy M., Goud K. S., Ramanjaneyulu K., Himabindu J., Raj K. S., Thalassemia-A Blood Disorder, its Cause, Prevention and Management, Research Journal of Pharmaceutical Dosage Forms and Technology, 11 (3) (2019) 186-190.
[8] Casu C., Oikonomidou P. R., Chen H., Nandi V., Ginzburg Y., Prasad P., Rivella S., Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera, Blood, The Journal of the American Society of Hematology, 128 (2) (2016) 265-276.

[9] Rauf A., Shariati M. A., Khalil A. A., Bawazeer S., Heydar M., Plygun S., Aljohani A. S. Hepcidin, an overview of biochemical and clinical properties, Steroids, 160 (2020) 108661.
[10] Keohane E. M., Otto C. N., Walenga J. M., Rodak's Hematology-E-Book: Rodak's Hematology-E-Book, Elsevier Health Sciences, (2019).
[11] Papanikolaou G., Tzilianos M., Christakis J. I., Bogdanos D., Tsimirika K., MacFarlane J., Nemeth E. Hepcidin in iron overload disorders, Blood, 105 (10) (2005) 4103-4105.
[12] Abd H. M., Al Samarrai O. R., Evaluation of hepcidin, ferritin and iron levels with liver enzymes of β-thalassemia patients in Diyala governorate, Iraq, In AIP Conference Proceedings, 2450 (1). (2022) AIP Publishing.
[13] Goodnough L. T., Iron deficiency syndromes and iron‐restricted erythropoiesis (CME), Transfusion, 52 (7) (2012) 1584-1592.
[14] Hasoon I. G., Shani W. S., Radi A. M., The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province, EurAsian Journal of BioSciences, 14 (2) (2020) 7285-7289.
[15] Neufeld E. J., Update on iron chelators in thalassemia, Hematology 2010, The American Society of Hematology Education Program Book, 2010 (1) (2010) 451-455.
[16] Kosman D. J., Redox cycling in iron uptake, efflux, and trafficking, Journal of Biological Chemistry, 285 (35) (2010) 26729-26735.
[17] Hosen M. B., Karmokar N. C., Karim M. F., Al Mahmud R., Mesbah, M., Association of AST, ALT, ALB and total protein with beta-thalassemia in Bangladeshi population, International Journal, 3 (1) (2015) 991-995.
[18] Abd I. K., Zainal I. G., Assessment of biochemical parameters and study its correlation in ß-Thalassemia major patients and healthy controls in Kirkuk City, Iraq, Medical Journal of Babylon, 17 (2) (2020) 172-176.
[19] Malik A. M., Malik E. M., Al-Shammaa N. M., Al-Rubaei Z. M., A Comparative Biochemical Study of Proteins Profile in Iraqi Children and Adolescent with β–Thalassemia, Iraqi J. Pharm. Sci., 19 (2) (2010) 19-23.
[20] Walter P. B., Macklin E. A., Porter J., Evans P., Kwiatkowski J. L., Neufeld E. J., Harmatz, P., Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial, Haematologica, 93 (6) (2008) 817-825.
[21] Pieniazek A., Gwozdzinski L., Zbrog Z., Gwozdzinski K., Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients, PLoS One, 13 (3) (2018) e0192268.
[22] Taverna M., Marie A. L., Mira J. P., Guidet B., Specific antioxidant properties of human serum albumin, Annals of Intensive Care, 3 (2013) 1-7.
[23] Oki S., Toiyama Y., Okugawa Y., Shimura T., Okigami M., Yasuda H., Kusunoki M., Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients, The American Journal of Surgery, 214 (5) (2017) 891-898.
[24] Althanoon Z. A., Alkazzaz N. A., Comparison of The Effects of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia, Systematic Reviews in Pharmacy, 11 (11) (2020).
[25] Ghazala M. M., Abdellateif S. S., Taher M. M. S., Abdelmohsen E. A., Bakheet O. H., Assem A. A. A., Serum hepcidin and growth differentiation factor 15 in patients with β-thalassemia and its relation to blood transfusion, Al-Azhar International Medical Journal, 2 (3) (2021) 43-48.
[26] Shanaki M., Ehteram H., Nasiri H., Azad M., Kouhkan F., Pakzad R., Mobarra N., Assessment of Liver and Kidney Functional Parameters along with oxidative Stress and Inflammatory Biomarker in Patients with β-Thalassemia major, Iranian Journal of Pediatric Hematology and Oncology, 6 (4) (2016) 249-260.
[27] Jalali A., Khalilian H., Ahmadzadeh A., Sarvestani S., Rahim F., Zandian K., Asar S., Renal function in transfusion-dependent pediatric beta-thalassemia major patients, Hematology, 16 (4) (2011) 249-254.
[28] Sadeghi-Bojd S., Hashemi M., Karimi M., Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran, Singapore Med. J., 49 (5) (2008) 410-2.
[29] Majeed A. M. H., Hameed O. R., Effect of endothelin-1, Vimentin and some biochemical variables on men with type 2 diabetes mellitus, diabetic patients with hypertension, and diabetic patients with renal impairment, Samarra Journal of Pure and Applied Science, 4 (3) (2022) 61-78.
[30] Younus Z. M., Alhially Y. A. H., Bashi A. Y. D., Evaluation of conventional renal function tests in β-thalassemia major patients in Nineveh province, Tikrit Journal of Pharmaceutical Sciences, 8(1) (2012) 6-14.

Details

Primary Language

English

Subjects

Analytical Biochemistry

Journal Section

Research Article

Authors

Othman R Al Samarraı ^*
0000-0002-1487-4054
Iraq

Hazem Mohammed Abd
0000-0002-8661-2985
Iraq

Mohammed Hameed Mahal
0000-0002-7207-3140
Iraq

Ali Rasheed Hameed Al Samarrai
0000-0001-9963-4449
Iraq

Publication Date

March 25, 2025

Submission Date

October 6, 2024

Acceptance Date

January 22, 2025

Published in Issue

Year 2025 Volume: 46 Number: 1

DOI

https://doi.org/10.17776/csj.1562338

IZ

https://izlik.org/JA65UP86BP

Cite

RIS / Bibtex

APA

Al Samarraı, O. R., Abd, H. M., Mahal, M. H., & Al Samarrai, A. R. H. (2025). Evaluation Of Hepcidin And Iron Concentrations With Liver And Kidney Functions In Beta-Thalassemia Patients. Cumhuriyet Science Journal, 46(1), 8-12. https://doi.org/10.17776/csj.1562338

Evaluation Of Hepcidin And Iron Concentrations With Liver And Kidney Functions In Beta-Thalassemia Patients

Abstract

Keywords

Öz

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite